![Gianni Garotta](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Relazioni attive
Nome | Sesso | Età | Società collegate | Collaborazione |
---|---|---|---|---|
Ferdinando Nicoletti | M | - |
OncoNOx ApS
![]() OncoNOx ApS Pharmaceuticals: MajorHealth Technology OncoNOx ApS provides drugs for the treatment of autoimmune diseases and cancer. It is a pharmaceutical company that transforms marketed drugs into proprietary molecules with anti-cancer and/or anti-inflammatory properties. The firm's projects include OX1001 and OX27-NO is a potent anti-cancer compounds in vitro and in vivo and are intended for the treatment of cancer, and OX1001 also exhibits anti-viral activity and is in development for treatment of human immunodeficiency virus (HIV) and acquired immune deficiency syndrome patients with or without HIV related cancer. The company was founded by Ferdinando Nicoletti, Gianni Garotta, Yousef Al-Abed, Marco Donia, and Mai-Britt Zocca in 2011 and is headquartered in Copenhagen, Denmark. | 13 anni |
Maurizio Denaro | M | - |
Natimab Therapeutics Srl
![]() Natimab Therapeutics Srl BiotechnologyHealth Technology Natimab Therapeutics Srl operates as a biotechnology company. It specializes in the identification and early-stage clinical development of monoclonal antibodies (mAbs) for the treatment of infectious diseases. The company was founded by Gianni Garotta, Maurizio Denaro, Marianne Murphy and Gerritt Hagens in 2009 and is headquartered in Colleretto Giacosa, Italy. | 15 anni |
Gerrit Hagens | M | - |
Natimab Therapeutics Srl
![]() Natimab Therapeutics Srl BiotechnologyHealth Technology Natimab Therapeutics Srl operates as a biotechnology company. It specializes in the identification and early-stage clinical development of monoclonal antibodies (mAbs) for the treatment of infectious diseases. The company was founded by Gianni Garotta, Maurizio Denaro, Marianne Murphy and Gerritt Hagens in 2009 and is headquartered in Colleretto Giacosa, Italy. | 15 anni |
Yousef Al-Abed | M | - |
OncoNOx ApS
![]() OncoNOx ApS Pharmaceuticals: MajorHealth Technology OncoNOx ApS provides drugs for the treatment of autoimmune diseases and cancer. It is a pharmaceutical company that transforms marketed drugs into proprietary molecules with anti-cancer and/or anti-inflammatory properties. The firm's projects include OX1001 and OX27-NO is a potent anti-cancer compounds in vitro and in vivo and are intended for the treatment of cancer, and OX1001 also exhibits anti-viral activity and is in development for treatment of human immunodeficiency virus (HIV) and acquired immune deficiency syndrome patients with or without HIV related cancer. The company was founded by Ferdinando Nicoletti, Gianni Garotta, Yousef Al-Abed, Marco Donia, and Mai-Britt Zocca in 2011 and is headquartered in Copenhagen, Denmark. | 13 anni |
Marco Donia | M | - |
OncoNOx ApS
![]() OncoNOx ApS Pharmaceuticals: MajorHealth Technology OncoNOx ApS provides drugs for the treatment of autoimmune diseases and cancer. It is a pharmaceutical company that transforms marketed drugs into proprietary molecules with anti-cancer and/or anti-inflammatory properties. The firm's projects include OX1001 and OX27-NO is a potent anti-cancer compounds in vitro and in vivo and are intended for the treatment of cancer, and OX1001 also exhibits anti-viral activity and is in development for treatment of human immunodeficiency virus (HIV) and acquired immune deficiency syndrome patients with or without HIV related cancer. The company was founded by Ferdinando Nicoletti, Gianni Garotta, Yousef Al-Abed, Marco Donia, and Mai-Britt Zocca in 2011 and is headquartered in Copenhagen, Denmark. | 13 anni |
Grafico relazionale
Relazione in diverse aziende
Relazioni precedenti
Nome | Sesso | Età | Società collegate | Collaborazione |
---|---|---|---|---|
Mai-Britt Zocca | M | 56 |
OncoNOx ApS
![]() OncoNOx ApS Pharmaceuticals: MajorHealth Technology OncoNOx ApS provides drugs for the treatment of autoimmune diseases and cancer. It is a pharmaceutical company that transforms marketed drugs into proprietary molecules with anti-cancer and/or anti-inflammatory properties. The firm's projects include OX1001 and OX27-NO is a potent anti-cancer compounds in vitro and in vivo and are intended for the treatment of cancer, and OX1001 also exhibits anti-viral activity and is in development for treatment of human immunodeficiency virus (HIV) and acquired immune deficiency syndrome patients with or without HIV related cancer. The company was founded by Ferdinando Nicoletti, Gianni Garotta, Yousef Al-Abed, Marco Donia, and Mai-Britt Zocca in 2011 and is headquartered in Copenhagen, Denmark. | 8 anni |
Hans Schambye | M | 59 |
OncoNOx ApS
![]() OncoNOx ApS Pharmaceuticals: MajorHealth Technology OncoNOx ApS provides drugs for the treatment of autoimmune diseases and cancer. It is a pharmaceutical company that transforms marketed drugs into proprietary molecules with anti-cancer and/or anti-inflammatory properties. The firm's projects include OX1001 and OX27-NO is a potent anti-cancer compounds in vitro and in vivo and are intended for the treatment of cancer, and OX1001 also exhibits anti-viral activity and is in development for treatment of human immunodeficiency virus (HIV) and acquired immune deficiency syndrome patients with or without HIV related cancer. The company was founded by Ferdinando Nicoletti, Gianni Garotta, Yousef Al-Abed, Marco Donia, and Mai-Britt Zocca in 2011 and is headquartered in Copenhagen, Denmark. | - |
Marianne Murphy | M | - |
Natimab Therapeutics Srl
![]() Natimab Therapeutics Srl BiotechnologyHealth Technology Natimab Therapeutics Srl operates as a biotechnology company. It specializes in the identification and early-stage clinical development of monoclonal antibodies (mAbs) for the treatment of infectious diseases. The company was founded by Gianni Garotta, Maurizio Denaro, Marianne Murphy and Gerritt Hagens in 2009 and is headquartered in Colleretto Giacosa, Italy. | - |
Statistiche
Paese | Relazioni | % del totale |
---|---|---|
Danimarca | 5 | 62.50% |
Italia | 3 | 37.50% |
Età delle relazioni
Attive
Scorse
Uomo
Donna
Amministratori
Dirigenti
Provenienza delle relazioni
- Borsa valori
- Insiders
- Gianni Garotta
- Contatti personali